Neville Rodie & Shaw Has Boosted Salesforce.Com (CRM) Stake; Last Week Tonix Pharmaceuticals Holding Corp. (TNXP) Analysts

Among 3 analysts covering Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Tonix Pharmaceuticals Holding Corp. has $18 highest and $6.0 lowest target. $11.33’s average target is 232.26% above currents $3.41 stock price. Tonix Pharmaceuticals Holding Corp. had 6 analyst reports since August 20, 2015 according to SRatingsIntel. On Thursday, August 20 the stock rating was maintained by Oppenheimer with “Outperform”. The firm has “Buy” rating by Roth Capital given on Friday, August 18. The rating was initiated by Aegis Capital with “Buy” on Monday, June 26. The company was maintained on Thursday, November 9 by Roth Capital. The company was initiated on Wednesday, November 4 by Cantor Fitzgerald. The firm has “Buy” rating by Cantor Fitzgerald given on Thursday, June 2. See Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) latest ratings:

09/11/2017 Broker: Roth Capital Rating: Buy New Target: $6.0 Maintain

Neville Rodie & Shaw Inc increased Salesforce.Com Inc (CRM) stake by 19.56% reported in 2017Q3 SEC filing. Neville Rodie & Shaw Inc acquired 3,926 shares as Salesforce.Com Inc (CRM)’s stock rose 7.28%. The Neville Rodie & Shaw Inc holds 23,999 shares with $2.24M value, up from 20,073 last quarter. Salesforce.Com Inc now has $91.57B valuation. The stock decreased 0.49% or $0.63 during the last trading session, reaching $126.78. About 5.61 million shares traded or 10.35% up from the average. Salesforce.com, inc. (NYSE:CRM) has risen 7.78% since March 13, 2017 and is uptrending. It has underperformed by 8.92% the S&P500.

Tonix Pharmaceuticals Holding Corp. engages in developing pharmaceutical and biological products to address public health challenges. The company has market cap of $26.70 million. The Company’s lead product candidate, TNX-102 SL or Tonmya, designed as a bedtime treatment for posttraumatic stress disorder , which is in Phase 3 study in the military-related PTSD population. It currently has negative earnings. The firm is also developing TNX-601 (tianeptine oxalate), a clinical candidate at pre-IND (investigational new drug) application stage, designed as a daytime treatment for posttraumatic stress disorder (PTSD); and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage.

The stock decreased 4.75% or $0.17 during the last trading session, reaching $3.41. About 96,064 shares traded or 42.44% up from the average. Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) has declined 82.55% since March 13, 2017 and is downtrending. It has underperformed by 99.25% the S&P500.

Since September 19, 2017, it had 2 insider buys, and 122 sales for $71.50 million activity. The insider Benioff Marc sold $569,062. Another trade for 268 shares valued at $31,436 was made by Allanson Joe on Tuesday, February 27. Another trade for 7,641 shares valued at $732,423 was sold by BLOCK KEITH. 250 shares valued at $27,713 were sold by Conway Craig on Tuesday, January 16. $194,269 worth of Salesforce.com, inc. (NYSE:CRM) shares were sold by Harris Parker. Roos John Victor had sold 129 shares worth $14,203. Hawkins Mark J sold $1.95M worth of Salesforce.com, inc. (NYSE:CRM) on Monday, February 26.

Investors sentiment decreased to 1.19 in Q3 2017. Its down 0.15, from 1.34 in 2017Q2. It dived, as 40 investors sold CRM shares while 234 reduced holdings. 73 funds opened positions while 295 raised stakes. 609.74 million shares or 0.30% less from 611.55 million shares in 2017Q2 were reported. Ahl Prtn Limited Liability Partnership holds 0.04% or 24,122 shares. Norinchukin National Bank The has 50,819 shares for 0.09% of their portfolio. Veritable LP has 17,333 shares for 0.03% of their portfolio. Fincl Counselors Inc holds 0.33% or 72,014 shares in its portfolio. Wellington Shields Capital Mgmt Ltd Liability Corporation has invested 0.18% in Salesforce.com, inc. (NYSE:CRM). Envestnet Asset Management has 72,133 shares for 0.02% of their portfolio. Franklin Res holds 3.42M shares. Fred Alger Mngmt accumulated 1.58% or 3.61 million shares. Tocqueville Asset Management LP invested 0.14% in Salesforce.com, inc. (NYSE:CRM). Falcon Edge LP has 222,700 shares. Arizona State Retirement Sys stated it has 0.19% of its portfolio in Salesforce.com, inc. (NYSE:CRM). Optimum Invest Advisors holds 2,605 shares. Vident Investment Advisory Limited Liability Corporation owns 10,104 shares. 18,127 are held by Tru Of Vermont. Gulf Savings Bank (Uk) invested 0.27% of its portfolio in Salesforce.com, inc. (NYSE:CRM).

Among 54 analysts covering Salesforce.com (NYSE:CRM), 48 have Buy rating, 1 Sell and 5 Hold. Therefore 89% are positive. Salesforce.com has $150.0 highest and $18 lowest target. $115.01’s average target is -9.28% below currents $126.78 stock price. Salesforce.com had 225 analyst reports since August 21, 2015 according to SRatingsIntel. On Wednesday, November 22 the stock rating was downgraded by Roth Capital to “Hold”. On Tuesday, November 15 the stock rating was upgraded by OTR Global to “Positive”. The firm earned “Buy” rating on Thursday, November 19 by UBS. On Thursday, May 19 the stock rating was maintained by JP Morgan with “Overweight”. The firm has “Buy” rating given on Thursday, November 19 by Needham. Deutsche Bank maintained it with “Buy” rating and $95 target in Thursday, May 19 report. Rosenblatt initiated the shares of CRM in report on Tuesday, October 18 with “Buy” rating. Oppenheimer maintained it with “Outperform” rating and $95 target in Thursday, May 19 report. The firm earned “Hold” rating on Thursday, February 16 by Needham. The firm earned “Buy” rating on Wednesday, August 23 by Piper Jaffray.